Promoter Methylation Status of Breast Cancer Susceptibility Gene 1 and 17 Beta Hydroxysteroid Dehydrogenase Type 1 Gene in Sporadic Breast Cancer Patients

Epigenetic modifications are involved in breast carcinogenesis. Identifying genes that are epigenetically silenced via methylation could select target patients for diagnostic as well as therapeutic potential. We assessed promoter methylation of breast cancer susceptibility gene 1 (BRCA1) and 17 Beta...

Full description

Saved in:
Bibliographic Details
Main Authors: Marwa M. Hosny, Nagwan A. Sabek, Taghrid B. El-Abaseri, Fathalla M. Hassan, Sherif H. Farrag
Format: Article
Language:English
Published: Wiley 2016-01-01
Series:International Journal of Breast Cancer
Online Access:http://dx.doi.org/10.1155/2016/9545241
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849692089836634112
author Marwa M. Hosny
Nagwan A. Sabek
Taghrid B. El-Abaseri
Fathalla M. Hassan
Sherif H. Farrag
author_facet Marwa M. Hosny
Nagwan A. Sabek
Taghrid B. El-Abaseri
Fathalla M. Hassan
Sherif H. Farrag
author_sort Marwa M. Hosny
collection DOAJ
description Epigenetic modifications are involved in breast carcinogenesis. Identifying genes that are epigenetically silenced via methylation could select target patients for diagnostic as well as therapeutic potential. We assessed promoter methylation of breast cancer susceptibility gene 1 (BRCA1) and 17 Beta Hydroxysteroid Dehydrogenase Type 1 (17βHSD-1) in normal and cancer breast tissues of forty sporadic breast cancer (BC) cases using restriction enzyme based methylation-specific PCR (REMS-PCR). In cancerous tissues, BRCA1 and 17βHSD-1 were methylated in 42.5% and 97.5%, respectively, while normal tissues had 35% and 95% methylation, respectively. BRCA1 methylation in normal tissues was 12.2-fold more likely to associate with methylation in cancer tissues (p<0.001). It correlated significantly with increased age at menopause, mitosis, the negative status of Her2, and the molecular subtype “luminal A” (p=0.048, p=0.042, p=0.007, and p=0.049, resp.). Methylation of BRCA1 and 17βHSD-1 related to luminal A subtype of breast cancer. Since a small proportion of normal breast epithelial cells had BRCA1 methylation, our preliminary findings suggest that methylation of BRCA1 may be involved in breast tumors initiation and progression; therefore, it could be used as a biomarker for the early detection of sporadic breast cancer. Methylation of 17βHSD-1 in normal and cancer tissue could save patients the long term use of adjuvant antiestrogen therapies.
format Article
id doaj-art-b0434d6bdd81478f97aea3dc0ae838ae
institution DOAJ
issn 2090-3170
2090-3189
language English
publishDate 2016-01-01
publisher Wiley
record_format Article
series International Journal of Breast Cancer
spelling doaj-art-b0434d6bdd81478f97aea3dc0ae838ae2025-08-20T03:20:50ZengWileyInternational Journal of Breast Cancer2090-31702090-31892016-01-01201610.1155/2016/95452419545241Promoter Methylation Status of Breast Cancer Susceptibility Gene 1 and 17 Beta Hydroxysteroid Dehydrogenase Type 1 Gene in Sporadic Breast Cancer PatientsMarwa M. Hosny0Nagwan A. Sabek1Taghrid B. El-Abaseri2Fathalla M. Hassan3Sherif H. Farrag4Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Suez Canal University, Round Road, Ismailia 41111, EgyptDepartment of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Suez Canal University, Round Road, Ismailia 41111, EgyptDepartment of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Suez Canal University, Round Road, Ismailia 41111, EgyptDepartment of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Suez Canal University, Round Road, Ismailia 41111, EgyptSurgery Department, Faculty of Medicine, Suez Canal University, Ismailia, EgyptEpigenetic modifications are involved in breast carcinogenesis. Identifying genes that are epigenetically silenced via methylation could select target patients for diagnostic as well as therapeutic potential. We assessed promoter methylation of breast cancer susceptibility gene 1 (BRCA1) and 17 Beta Hydroxysteroid Dehydrogenase Type 1 (17βHSD-1) in normal and cancer breast tissues of forty sporadic breast cancer (BC) cases using restriction enzyme based methylation-specific PCR (REMS-PCR). In cancerous tissues, BRCA1 and 17βHSD-1 were methylated in 42.5% and 97.5%, respectively, while normal tissues had 35% and 95% methylation, respectively. BRCA1 methylation in normal tissues was 12.2-fold more likely to associate with methylation in cancer tissues (p<0.001). It correlated significantly with increased age at menopause, mitosis, the negative status of Her2, and the molecular subtype “luminal A” (p=0.048, p=0.042, p=0.007, and p=0.049, resp.). Methylation of BRCA1 and 17βHSD-1 related to luminal A subtype of breast cancer. Since a small proportion of normal breast epithelial cells had BRCA1 methylation, our preliminary findings suggest that methylation of BRCA1 may be involved in breast tumors initiation and progression; therefore, it could be used as a biomarker for the early detection of sporadic breast cancer. Methylation of 17βHSD-1 in normal and cancer tissue could save patients the long term use of adjuvant antiestrogen therapies.http://dx.doi.org/10.1155/2016/9545241
spellingShingle Marwa M. Hosny
Nagwan A. Sabek
Taghrid B. El-Abaseri
Fathalla M. Hassan
Sherif H. Farrag
Promoter Methylation Status of Breast Cancer Susceptibility Gene 1 and 17 Beta Hydroxysteroid Dehydrogenase Type 1 Gene in Sporadic Breast Cancer Patients
International Journal of Breast Cancer
title Promoter Methylation Status of Breast Cancer Susceptibility Gene 1 and 17 Beta Hydroxysteroid Dehydrogenase Type 1 Gene in Sporadic Breast Cancer Patients
title_full Promoter Methylation Status of Breast Cancer Susceptibility Gene 1 and 17 Beta Hydroxysteroid Dehydrogenase Type 1 Gene in Sporadic Breast Cancer Patients
title_fullStr Promoter Methylation Status of Breast Cancer Susceptibility Gene 1 and 17 Beta Hydroxysteroid Dehydrogenase Type 1 Gene in Sporadic Breast Cancer Patients
title_full_unstemmed Promoter Methylation Status of Breast Cancer Susceptibility Gene 1 and 17 Beta Hydroxysteroid Dehydrogenase Type 1 Gene in Sporadic Breast Cancer Patients
title_short Promoter Methylation Status of Breast Cancer Susceptibility Gene 1 and 17 Beta Hydroxysteroid Dehydrogenase Type 1 Gene in Sporadic Breast Cancer Patients
title_sort promoter methylation status of breast cancer susceptibility gene 1 and 17 beta hydroxysteroid dehydrogenase type 1 gene in sporadic breast cancer patients
url http://dx.doi.org/10.1155/2016/9545241
work_keys_str_mv AT marwamhosny promotermethylationstatusofbreastcancersusceptibilitygene1and17betahydroxysteroiddehydrogenasetype1geneinsporadicbreastcancerpatients
AT nagwanasabek promotermethylationstatusofbreastcancersusceptibilitygene1and17betahydroxysteroiddehydrogenasetype1geneinsporadicbreastcancerpatients
AT taghridbelabaseri promotermethylationstatusofbreastcancersusceptibilitygene1and17betahydroxysteroiddehydrogenasetype1geneinsporadicbreastcancerpatients
AT fathallamhassan promotermethylationstatusofbreastcancersusceptibilitygene1and17betahydroxysteroiddehydrogenasetype1geneinsporadicbreastcancerpatients
AT sherifhfarrag promotermethylationstatusofbreastcancersusceptibilitygene1and17betahydroxysteroiddehydrogenasetype1geneinsporadicbreastcancerpatients